Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
102314 trials found · Page 169 of 5116
-
New pill targets genetic weakness in Hard-to-Treat leukemia
Disease control Not yet recruitingThis phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy. AML is often due to genetic changes in the cancer cells, including mutations in the NPM1 g…
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 10, 2026 06:56 UTC
-
New hope for liver cancer: combo therapy aims to boost immune attack
Disease control Recruiting nowRBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby ac…
Phase: PHASE2 • Sponsor: Riboscience, LLC. • Aim: Disease control
Last updated Jun 08, 2026 13:03 UTC
-
New combo therapy aims to slow advanced pancreatic cancer
Disease control Recruiting nowAdvanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 10, 2026 06:56 UTC
-
Chemo cocktail offers hope to bladder cancer patients facing organ removal
Disease control Recruiting nowThe goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasive bladder cancer (HG-NMIBC) in adults whose cancer failed conventional BCG therapy. The drugs are given directly into the…
Phase: PHASE2 • Sponsor: Michael A. O'Donnell • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
Engineered immune cells take on multiple sclerosis and other nerve disorders
Disease control Recruiting nowThis study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary obje…
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 10, 2026 06:55 UTC
-
Can a simple stitch save twin pregnancies from early delivery?
Prevention Recruiting nowThis study aims to compare the effectiveness of cervical cerclage combined with progesterone versus progesterone alone in preventing preterm birth among women with twin pregnancies and a short cervix (cervical length ≤ 30 mm). Participants will be randomly allocated to either the…
Phase: NA • Sponsor: National Hospital of Obstetrics and Gynecology • Aim: Prevention
Last updated Jun 05, 2026 12:08 UTC
-
New drug duo offers hope for advanced penile cancer patients
Disease control Recruiting nowThis phase II clinical study aims to evaluate the efficacy and safety of QL1706 in combination with lenvatinib in patients with previously treated advanced or metastatic penile squamous cell carcinoma. The primary objective of the study is to determine the median progression-fre…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC
-
New lupus drug shows promise in phase 3 trial
Disease control Recruiting nowThis study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.
Phase: PHASE3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC
-
New drug combo shows promise in shrinking tough colon tumors before surgery
Disease control Recruiting nowThis multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally advanced colon adenocarcinoma (cT3c+). 106 patients …
Phase: PHASE2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated May 27, 2026 12:02 UTC
-
New triple therapy may boost leukemia remission in seniors
Disease control Not yet recruitingThis is a multicenter, open-label, randomized, controlled phase III clinical trial designed to evaluate the efficacy and safety of the combination of Venetoclax, Azacitidine, and Homoharringtonine (VAH) compared to Venetoclax and Azacitidine (VA) alone in newly diagnosed elderly …
Phase: PHASE3 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 05, 2026 12:09 UTC
-
New radiation therapy targets tough lung cancer tumors
Disease control Not yet recruitingNon-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and accounts for approximately 80% of all lung cancer cases. Despite advances in chemotherapy, radiotherapy, and immunotherapy, the prognosis of patients with advanced-stage metastatic N…
Phase: PHASE2 • Sponsor: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization • Aim: Disease control
Last updated May 27, 2026 12:00 UTC
-
New stem cell approach aims to improve survival in blood cancer patients
Disease control Recruiting nowThis is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophyl…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 08, 2026 13:13 UTC
-
New combo therapy offers hope for Hard-to-Treat throat cancer
Disease control Not yet recruitingThe investigators plan to conduct a multicenter, prospective, single-arm phase II clinical trial of PD-1 monoclonal antibody combined with gemcitabine and cisplatin followed by selective radiotherapy for unresectable locally recurrent nasopharyngeal carcinoma to evaluate the effi…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug trial hopes to shrink brain tumors
Disease control Recruiting nowThe purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 27, 2026 11:50 UTC
-
New drug combo shows promise for untreatable liver cancer in early trial
Disease control Not yet recruitinghis is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX …
Phase: PHASE2 • Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC
-
New combo therapy aims to outsmart follicular lymphoma
Disease control Not yet recruitingThe purpose of this prospective, multicenter, Phase 2 study is to evaluate the efficacy and safety of Mosunetuzumab in combination with the EZH2 inhibitor Zeprumetostat (SHR2554) in patients with follicular lymphoma (FL). The study plans to enroll approximately 80 patients, who w…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
New drug combo aims to shrink advanced cervical tumors
Disease control Not yet recruitingThis is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1/CTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed …
Phase: PHASE1, PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC
-
New hope for advanced liver cancer patients who failed prior treatments
Disease control Not yet recruitingThis is a randomized, open-label, multicenter Phase Ib/II registration trial designed to evaluate the efficacy and safety of HH-009 in patients with FGF19-positive hepatocellular carcinoma (HCC). The study will also assess pharmacokinetics, pharmacodynamics, immunogenicity, and e…
Phase: PHASE1, PHASE2 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 10, 2026 06:56 UTC
-
Stoma fluid recycling may stop post-surgery bowel chaos
Prevention Recruiting nowThe goal of this clinical trial is to learn if antegrade intestinal fluid reinfusion works to prevent low anterior resection syndrome (LARS) in patients with prophylactic ileal stoma. The main questions it aims to answer are: 1. Does it work to prevent LARS by antegrade intestin…
Phase: PHASE2, PHASE3 • Sponsor: Pei-Rong Ding • Aim: Prevention
Last updated Jun 10, 2026 06:53 UTC
-
New stem cell therapy aims to ease hardening skin in rare autoimmune disease
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection(HS\_SW01 Cells injection) in patients with systemic sclerosis, and to further explore its pharmacokinetics(PK), immunological profile and preliminary…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Huishan Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 02, 2026 11:58 UTC